IMPROVE trial 3 year results Interim results for Vascular Society

1st December 2016, Manchester

Immediate Management of the Patient with Rupture: Open Versus Endovascular Repair



www.improvetrial.org






Project number 07/37/64

The team

Trial Management Committee Janet T Powell Pinar Ulug Michael Sweeting Rob Hinchliffe Matt Thompson Ray Ashleigh **Manuel Gomes Richard Grieve** Roger Greenhalgh **Simon Thompson**




Credentialled centres 29 UK, 1 Canada



final diagnoses

For patients with an in-hospital clinical diagnosis of rupture, before CT



Rupture = blood outside aneurysm sac, core laboratory Other diagnoses 45/55 with asymptomatic AAA + 1/55 TAAA

Baseline characteristics by randomised group

Variable	Endovascular strategy, N=316	Open repair N=297
Age (years)	76.7 (7.4)	76.7 (7.8)
Males (%)	246 (78%)	234 (79%)
Hardman Index n (%)		
0	93 (33%)	69 (27%)
1	130 (46%)	126 (49%)
2+	59 (21%)	62 (24%)
Max aortic diameter (cm)	8.4 (1.9)	8.1 (1.8)



IMPR VEtrial Summary of published data



30-day mortality **Endovascular strategy 35%** Open repair 37%

Endovascular strategy more effective in women





FASTTRACK CLINICAL RESEARCH Cardiovascular surgery

Endovascular strategy or open repair for ruptured abdominal aortic aneurysm: one-year outcomes from the IMPROVE randomized trial

IMPROVE Trial Investigators†

Received 7 March 2015; revised 23 March 2015; accepted 26 March 2015; online publish-ahead-of-brint 8 April 2015

1 year **Endovascular strategy Better quality of life Lower costs Cost-effective**

But no difference in mortality, although still more effective in women

Correspondence to: JT Powell, Vascular Surgery Research Group, Imperial College, London Wei 69P, UK j powell@imperial.ac.uk Extra material supplied by the author (see http://www.bmj.com/content/348/bmj.17861?ab-related#



VEtrial Aims of 3 year follow up

To assess for an endovascular strategy vs open repair:

- Mid-term survival
- Impact of re-interventions
- Quality of life
- Mid-term costs
- Full cost-effectiveness




interim


Delays at NHS Digital to provide re-intervention data at non-trial hospitals & causes of death

Survival to 3 years and beyond

0-3m 91% deaths AAA-related 3m-3y 13% deaths AAA-related



Subgroup analyses: again endovascular strategy is At 3 years most effective in women



Quality of life is better in the endovascular strategy group in year 1, but similar by 3 years

Group	EQ5D utility score mean (SD) at		
	3m	12m	3 years
Endovascular strategy	0.76 (0.24)	0.77 (0.20)	0.72 (0.27)
Open repair	0.67 (0.32)	0.71 (0.33)	0.73 (0.32)
	P=0.015	P=0.059	P=0.894

>0.03 difference is clinically significant

At 3y quality adjusted life years higher in the endovascular strategy group

Group	QALYs at 3 years	
	Mean (SD)	Mean difference (95% CI)
Endovascular strategy	1.21 (1.11)	0.171 [-0.006, 0.349]
Open repair	1.04 (1.10)	P=0.058

At 3 years EVAR strategy is on average £2263 (12%) cheaper Endovascular strategy is likely to be cost-effective over 3 years


Re-interventions to 3 years Interim data

- HES data for re-interventions at non-trial hospitals pending
- AAA-related re-interventions (502 patients with repair of rupture)
- Categorized as arterial, laparotomy-related, other
- Categorized by a severity scoring system
- Also reported by potentially life-changing effects for patients

Survival without an AAA-related re-intervention


502 patients with repair ruptured AAA started

Interim results



Time to first serious re-intervention


3m to 3y possibly more minor reinterventions in endovascular strategy group



Type 1 endoleaks after completed EVAR total 186, 140 alive at 30 days

interim

Cumulative incidence of re-interventions for type 1 endoleak



Potentially life-changing events for patients

by treatment received

interim

Event	EVAR N=186	Open repair N=316
2º rupture	3	
Graft infection	2 both fem-fem total 36 AUI	4 all aortic
Delayed conversion to open repair	1	
Major amputation	1	7
Unclosed ileostomy/ colostomy	1	7

Interim 3 year results: endovascular strategy probably remains cost-effective

Outcome	Endovascular strategy (compared with open repair)
Survival	No benefit at 30d, 1y Borderline benefit at 3y Better for women throughout
Re-interventions	Probably little difference but fewer severe outcomes for patients
Quality of life	Better at 3m & 1y, no difference at 3y
QALYs	Gain at all time points
Costs	Non-significantly lower throughout

